Clinical trials: Minimal Disease, Residual
Ovarian Cancer
SEQUENTIAL PROFILING OF TUMOR-DERIVED CIRCULATING CELL-FREE DNA (ctDNA) IN ADVANCED OVARIAN CANCER PATIENTS
Ovarian cancer (OC) is the third most common gynaecologic cancer worldwide and has the highest mortality rate among gynaecologic cancers.
- Trial name
- SPEED (NCT06071286)
- Testing
- Blood samples
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Multiple Myeloma
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Evaluate the efficacy of DVRd in patients with newly diagnosed double-hit multiple myeloma (MM) and the feasibility of minimal residual disease (MRD) guided maintenance therapy
- Trial name
- NCT06158269
- Testing
- DVRd
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.
The aim of our study is to confirm the relevance of PET using [68Ga]Ga-PentixaFor ligand, in comparison with FDG, for initial staging and detection of minimal residual disease in multiple myeloma patients eligible for autologous…
- Trial name
- PENTI-MIDAS (NCT05321862)
- Testing
- [68Ga]Ga-PentixaFor
- Where
- France
- Sponsor
- Nantes University Hospital
ALL, MRD-positive
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
As part of postremission consolidative therapy, the decision to proceed with hematopoietic stem cell transplantation is a recommendable regimen in ALL therapy. However, The recurrence rate is high after transplantation.
- Conditions
- ALL, MRD-positive, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT05940961
- Testing
- Inotuzumab Ozogamicin
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sheng-Li Xue, MD
Multiple Myeloma
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.
- Trial name
- HEME-20 (NCT05192122)
- Testing
- Discontinue maintenance therapy SOC
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Illinois Chicago
Waldenstrom Macroglobulinemia
Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS
Multicenter retrospective and prospective observational study including patients with WM or IgM-MGUS evaluated at the time of diagnosis and during the disease course using highly sensitive techniques.
- Trial name
- FIL_BIOWM (NCT03521596)
- Testing
- MRD and clonal evolution
- Where
- 15 sites in Italy, Spain
- Volunteers
- 300 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Newly Diagnosed, High Risk
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
The goal of this study is to evaluate sustained MRD negativity for one year in DKRD induction \& consolidation therapy +/- ASCT in newly diagnosed high-risk multiple myeloma patients.
- Conditions
- Newly Diagnosed, High Risk, MRD, Multiple Myeloma
- Trial name
- NCT06409702
- Testing
- Carfilzomib, Daratumumab, Lenalidomide
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
This is a non-therapeutic study. Pediatric AML patients undergoing HCT with a myeloablative preparative regimen may be enrolled. Subjects can be enrolled 10-40 days prior to HCT.
- Trial name
- NCT01385787
- Where
- 38 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Adult Acute Lymphocytic Leukemia
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for…
- Trial name
- NCT00198991
- Testing
- Cyclophosphamide, Dexamethasone, Vincristine
- Where
- Germany
- Volunteers
- 1,883 people
- Sponsor
- Goethe University
ALL, Recurrent, Adult
Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
This study is designed to confirm the efficacy, safety, and tolerability of blinatumomab in patients with MRD of B- precursor ALL in complete hematological remission including patients with relapse after SCT.
- Trial name
- NCT03109093
- Testing
- Blinatumomab
- Where
- 22 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Goethe University
Chronic Lymphocytic Leukemia, Minimal Residual Disease
Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia
Chronic lymphocytic leukaemia (CLL) is the most common adult blood cancer in the United Kingdom. CLL means that many cancer cells appear in the blood, bone marrow and other tissues, for example, the spleen where some blood cells…
- Trial name
- NCT05093192
- Testing
- Exercise trial
- Where
- 2 sites in United Kingdom
- Volunteers
- 26 people
- Sponsor
- University of Bath
Chronic Myeloid Leukemia, Minimal Residual Disease
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
The goal of this clinical research study is to learn if giving 1 of 2 CML (Chronic Myeloid Leukemia) vaccines (CML-VAX B2 or CML-VAX B3) together with imatinib mesylate can decrease or eliminate all evidence of disease in…
- Trial name
- NCT00267085
- Testing
- Synthetic Tumor-Specific Breakpoint Peptide Vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloblastic Leukemia
Treatment of Acute Myeloblastic Leukemia in Younger Patients
study of the value of the cytogenetics and the monitoring of the residual minimum disease in the standard treatment of acute myeloblastic leukemia.
- Trial name
- NCT00390715
- Testing
- chemotherapy
- Where
- 42 sites in Spain
- Volunteers
- 600 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
Risk Stratification and MRD-driven Maintenance for MM After ASCT
This study evaluates the maintenance strategy based on risk stratification and MRD status after stem cell transplantation. This is a single-arm, multicenter, prospective study.
- Trial name
- NCT06697483
- Testing
- Daratumumab, Lenalidomide
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Colo-rectal Cancer
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive…
- Trial name
- EMPIRE (NCT07058012)
- Testing
- Cemiplimab, cemiplimab plus fianlimab, cemiplimab + REGN7075
- Where
- 13 sites in United States
- Volunteers
- 79 people
- Sponsor
- NSABP Foundation Inc
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
This phase I trial studies the side effects and the best dose of genetically modified T-cells after lymphodepleting chemotherapy in treating patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm…
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia
- Trial name
- NCT02159495
- Testing
- cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Minimal Residual Disease, Esophageal Squamous Cell Carcinoma
Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
This project is focusing on who have locally advanced esophageal squamous cell carcinoma and have undergone neoadjuvant and adjuvant therapy, followed by surgical resection.
- Trial name
- NCT05900583
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangdong Provincial People's Hospital
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
This phase I studies the side effects and best dose of total marrow and lymphoid irradiation when given together with fludarabine and melphalan before donor stem cell transplant in treating participants with high-risk acute…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission
- Trial name
- NCT03494569
- Testing
- Fludarabine, Laboratory Biomarker Analysis, Melphalan
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Relapsed Acute Lymphoblastic Leukemia, Relapsed Acute Myelogenous Leukemia
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
This is a phase I trial of an investigational drug called GNKG168 in patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) who are in morphologic remission but are positive…
- Trial name
- NCT01743807
- Testing
- GNKG168
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
HPV Positive Oropharyngeal Squamous Cell Carcinoma
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
The purpose of this study is to test a new liquid biopsy assay for detecting residual disease after surgery in patients with HPV-associated head and neck cancer.
- Trial name
- Clear-HPVca (NCT06730412)
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Massachusetts Eye and Ear Infirmary